Key Takeaways
- • Norstella launched the Pipeline-to-Patient Productivity Index (P3i), the first annual benchmark tracking R&D productivity, market access, and commercial return across the top 25 global biopharma companies across the entire drug development and commercialization lifecycle.
- • Eli Lilly ranks first in the inaugural P3i, rising from a hypothetical 16th place position against 2020 benchmarks, driven by operational improvements across its pipeline rather than reliance on GLP-1 franchise success alone.
- • The P3i is powered by Norstella's integrated data platform combining Citeline, Evaluate, and MMIT datasets, enabling institutional investors and biopharma executives to make informed capital allocation and portfolio decisions.
- • The inaugural index reveals significant inflationary pressures on R&D spending across the sector, a critical finding for hedge funds and institutional investors modeling pharma company profitability and return on investment.
- • The benchmark addresses a structural gap in pharma industry performance measurement, providing the first comprehensive "scoreboard" that follows molecular candidates from initial disclosure through clinical development, regulatory approval, market access, and commercial returns.
Summary
Norstella, a leading provider of AI-enabled pharmaceutical intelligence solutions, announced the launch of the Pipeline-to-Patient Productivity Index (P3i), establishing a new industry standard for benchmarking biopharma R&D performance. The P3i is the first comprehensive annual benchmark to track drug candidates across the entire development and commercialization lifecycle—from initial pipeline disclosure through clinical trials, regulatory approval, market access, and eventual commercial return. This full-cycle measurement capability distinguishes the P3i from existing pharma metrics, which typically focus on isolated segments of the drug development process.
The index covers the top 25 global biopharma companies and is designed to support institutional capital allocation decisions and portfolio strategy. According to Mike Gallup, CEO of Norstella, the benchmark addresses a fundamental gap in pharma industry measurement: "Pharmaceutical R&D is one of the largest sustained investments any industry makes. It deserves a clearer scoreboard than the one it has." The P3i provides that unified measurement framework by integrating data from Norstella's combined platforms—Citeline, Evaluate, and MMIT—creating a connected dataset of pharmaceutical intelligence across the value chain.
The inaugural P3i rankings reveal Eli Lilly as the top-performing company among the tracked biopharma firms. This positioning represents a substantial rise for Lilly, which would have ranked approximately 16th against equivalent 2020 benchmarks. Notably, Norstella attributes Lilly's improvement to broad operational enhancements across its pipeline rather than concentration in a single therapeutic area, suggesting the company has achieved productivity gains through systematic portfolio management rather than dependence on blockbuster assets such as GLP-1 therapies.
A significant finding from the inaugural report is the exposure of considerable inflationary pressures on R&D spending across the top 25 companies. This data point carries direct relevance for institutional investors modeling pharma sector fundamentals, as rising development costs compress margins and extend the capital recovery timeline for new therapeutics. For hedge funds and family offices with pharma sector exposure, the P3i provides quantified evidence of cost structure headwinds affecting industry-wide profitability and return metrics.
The P3i is positioned as an annual benchmark, indicating that Norstella intends to publish updated rankings and comparative data on a recurring basis, enabling investors to track productivity trends and competitive positioning shifts across the biopharma sector over time.
The index covers the top 25 global biopharma companies and is designed to support institutional capital allocation decisions and portfolio strategy. According to Mike Gallup, CEO of Norstella, the benchmark addresses a fundamental gap in pharma industry measurement: "Pharmaceutical R&D is one of the largest sustained investments any industry makes. It deserves a clearer scoreboard than the one it has." The P3i provides that unified measurement framework by integrating data from Norstella's combined platforms—Citeline, Evaluate, and MMIT—creating a connected dataset of pharmaceutical intelligence across the value chain.
The inaugural P3i rankings reveal Eli Lilly as the top-performing company among the tracked biopharma firms. This positioning represents a substantial rise for Lilly, which would have ranked approximately 16th against equivalent 2020 benchmarks. Notably, Norstella attributes Lilly's improvement to broad operational enhancements across its pipeline rather than concentration in a single therapeutic area, suggesting the company has achieved productivity gains through systematic portfolio management rather than dependence on blockbuster assets such as GLP-1 therapies.
A significant finding from the inaugural report is the exposure of considerable inflationary pressures on R&D spending across the top 25 companies. This data point carries direct relevance for institutional investors modeling pharma sector fundamentals, as rising development costs compress margins and extend the capital recovery timeline for new therapeutics. For hedge funds and family offices with pharma sector exposure, the P3i provides quantified evidence of cost structure headwinds affecting industry-wide profitability and return metrics.
The P3i is positioned as an annual benchmark, indicating that Norstella intends to publish updated rankings and comparative data on a recurring basis, enabling investors to track productivity trends and competitive positioning shifts across the biopharma sector over time.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.